Australian Pharma Stock News

Atlas Arteria (ASX:ALX) has drawn attention after reporting full year 2025 results, with revenue of A$160 million, net income of A$259.5 million and earnings per share easing alongside a 20 cent second half distribution declaration. See our latest analysis for Atlas Arteria. Atlas Arteria’s A$4.76 share price reflects a modest 1-year total shareholder return of 2.42%, while the 3-year total shareholder return decline of 11.16% suggests momentum has been softer despite the latest earnings and...

Paladin Energy Ltd. has received Ministerial approval for its Environmental Impact Statement under Saskatchewan’s Environmental Assessment Act, clearing a key regulatory hurdle for developing the shallow, high-grade Patterson Lake South uranium project in Canada’s Athabasca Basin. This approval is a prerequisite for future construction and operating permits, meaning regulatory risk around one of Paladin’s core growth assets has materially reduced. We’ll now examine how Ministerial approval...

APA Group (ASX:APA) has just received Australian Energy Regulator approval for A$459.5 million in regulated revenue from its Basslink interconnector over four years, which reshapes the certainty and risk profile around this core asset. See our latest analysis for APA Group. APA’s latest share price of A$9.29 comes after a 4.85% 1 month share price return and a 2.77% year to date share price gain. The 1 year total shareholder return of 33.18% points to stronger momentum over a longer...

Regis Resources (ASX:RRL) has caught investor attention after reporting half year 2025 earnings with sales of A$1,088.05 million and net income of A$322.75 million, alongside a fully franked interim dividend. See our latest analysis for Regis Resources. Those earnings and the fully franked interim dividend arrive after a strong run, with a 30 day share price return of 18.36% and a 1 year total shareholder return of 198.26%. However, the 1 day share price return of a 2.25% decline hints at...

In February 2026, Lynas Rare Earths reported half-year results to 31 December 2025 showing sales of A$413.69 million and net income of A$80.21 million, while Malaysia renewed the company’s operating license for 10 years with conditions to halt radioactive waste production by 2031 and treat existing waste. The sharp jump in profitability alongside a longer-dated but more tightly conditioned Malaysian license reshapes how investors may weigh Lynas’s regulatory risk against its operational...

Technical momentum puts Evolution Mining (ASX:EVN) in focus Recent technical reports flag Evolution Mining (ASX:EVN) as a stock with strong price momentum and rising demand, a pattern that appears to mirror the sharp pickup in investor interest. For you, this kind of momentum driven attention can be a prompt to look more closely at how the company’s fundamentals and valuation line up with its recent share price moves. See our latest analysis for Evolution Mining. Evolution Mining’s recent...

Pantoro Gold Limited (ASX:PNR) announced on 23 February 2026 that it had authorized an on-market share repurchase program of up to 38,344,473 shares, or 9.73% of its 394,180,907 shares on issue, running until 9 March 2027. This sizeable buyback capacity gives Pantoro Gold flexibility to adjust its capital structure over time, potentially increasing the ownership percentage of remaining shareholders if the program is executed. We will now examine how Pantoro Gold’s sizable share repurchase...

Perenti Limited recently reported half-year 2025 results showing broadly flat revenue of A$1,728.68 million and a modest increase in net income to A$58.34 million, alongside a higher unfranked interim dividend of A$0.0325 per share payable in April 2026. At the same time, the company trimmed the upper end of its fiscal 2026 revenue and EBIT guidance ranges and disclosed the upcoming resignation of Non-executive Director Tim Longstaff, adding a layer of uncertainty around its medium-term...

Earnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year. See our latest analysis for Neuren Pharmaceuticals. The share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...

Viva Energy Group Limited has reported full-year 2025 results showing sales of A$28.53 billion and a net loss of A$421.1 million, while also declaring a fully franked ordinary dividend of A$0.0394 per share for the six months to 31 December 2025, payable on 31 March 2026. The combination of a much larger loss and the decision to maintain a fully franked dividend raises important questions about Viva Energy’s earnings quality, cash generation, and approach to shareholder returns. We’ll now...

Cochlear has launched the Cochlear Nucleus Nexa System, described as the world's first smart cochlear implant with upgradeable firmware and on-implant memory for securely stored, personalized hearing settings, now available in India from 1 March 2026. This marks a meaningful step in digitising hearing care, potentially making future sound processor upgrades simpler and more efficient for both patients and clinicians. We’ll now examine how this smart, upgradeable implant platform could...

Elsight (ASX:ELS) has reported its full year 2025 results, with sales of US$22.8 million and net income of US$7.48 million, a shift from the prior year’s net loss. See our latest analysis for Elsight. The latest full year results arrive alongside very strong share price momentum. A 1 day share price return of 8.67% and a 90 day share price return of 170.53% have helped lift the 1 year total shareholder return to a very large gain, which suggests investors have rapidly reappraised both growth...

Why Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations. The company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million. See our latest analysis for...

Telix Pharmaceuticals (ASX:TLX) has entered an AI research collaboration with University Hospital Essen focused on PSMA-PET imaging in prostate cancer. The partnership will use Telix’s AI tools and the PROMISE-PET registry to build prognostic models for prostate cancer imaging. Telix has also submitted a European marketing authorization application for TLX101-Px, an advanced glioma imaging candidate. The glioma submission aims to address the need for more consistent, high-quality brain...

Mineral Resources (ASX:MIN) has drawn fresh attention after reporting half year earnings to 31 December 2025, with sales of A$3,052 million and net income of A$495 million, compared with a net loss a year earlier. See our latest analysis for Mineral Resources. The earnings rebound sits alongside a 26.5% 90 day share price return and a very large 1 year total shareholder return of about 2.5x, while the 3 year total shareholder return remains negative. This suggests that momentum is building...

TPG Telecom Limited recently reported full-year 2025 results, with revenue of A$5,041 million and net income of A$461 million, and declared an ordinary dividend of A$0.09 per share for the six months ended 31 December 2025, payable on 2 April 2026 to shareholders on record as of 6 March 2026. The return to profit, alongside network coverage expansion to 98.5% of the population and growing mobile service revenue from digital-first brands, highlights how TPG Telecom is converting past...

Why Ramelius Resources (ASX:RMS) is back on investors’ radar Ramelius Resources (ASX:RMS) packed several key updates into its 19 February announcement, including a move to a half year net loss, lower gold production, fresh 2026 guidance and a larger revolving facility. See our latest analysis for Ramelius Resources. Despite the half year net loss, lower production and facility refinancing, Ramelius Resources’ recent 1 day share price return of 4.36% sits within a stronger trend. The company...

Santos Limited recently reported full-year 2025 results showing net income of US$818 million, down from US$1.22 billion a year earlier, and declared a US$0.103 per share dividend for the six months ended 31 December 2025, payable on 25 March 2026. The company also confirmed unchanged 2026 production and sales guidance of 101–111 mmboe and announced the upcoming retirement of long-serving Non-Executive Director Yasmin Allen in February 2026, underscoring both operational continuity and...

South32 (ASX:S32) has moved back into the spotlight after Stephen Pearce took over as Chair following Karen Wood AM’s retirement, prompting investors to reassess the miner’s recent share gains and operational progress. See our latest analysis for South32. South32’s recent leadership change comes after a strong run in the share price, with the stock delivering a 42.22% 90 day share price return and a 34.91% 1 year total shareholder return from a latest share price of A$4.75. This suggests...

BHP Group (ASX:BHP) is back in focus after reporting a stronger than expected half year profit, with copper now contributing 51% of operating earnings and overtaking iron ore for the first time. See our latest analysis for BHP Group. The half year result, higher copper contribution and new production guidance have coincided with strong momentum, with BHP’s share price return of 39.22% over 90 days and a 56.07% total shareholder return over one year from dividends and price gains. If this...

What triggered fresh interest in Redox shares Redox (ASX:RDX) has come into focus after declaring an ordinary fully paid dividend of A$0.065 per share, alongside half year results to 31 December 2025, which reported higher sales and net income than a year earlier. See our latest analysis for Redox. The earnings and dividend announcement has arrived alongside a 1-day share price return of 3.12% to A$3.31, following a 90-day share price return of 15.33% and a 1-year total shareholder return of...

Macmahon Holdings Limited recently reported improved half-year results to 31 December 2025, lifted its fully franked interim dividend to A$0.0095 per share, reaffirmed FY26 earnings guidance, and earlier this year added experienced executive Tom Quinn as an Independent Non-Executive Director effective 16 March 2026. The combination of higher earnings, a larger dividend payout ratio aligned with its updated policy, and board refresh with cross-sector expertise may influence how investors...

Eagers Automotive Limited recently reported full-year 2025 results, with sales rising to A$13.05 billion and net income to A$226.66 million, and it also declared an ordinary dividend of A$0.50 per share for the six months ended 31 December 2025, paid on 19 March 2026. The combination of higher earnings per share from continuing operations and a cash dividend underscores the company’s ability to convert revenue into distributable profits for shareholders. We’ll now examine how this higher...

Red Hill Minerals (ASX:RHI) has put fresh numbers on the board for H1 2026, with the trailing 12 month picture showing revenue of A$21.9 million, basic EPS of A$0.25 and net income of A$16.1 million as investors weigh what this means at the current A$5.16 share price. The company has seen revenue move from A$0.28 million in H2 2024 to A$3.79 million in H1 2025 and A$8.10 million in H2 2025, alongside basic EPS of A$2.42, A$0.06 and A$0.09 across those halves. This sets a clear context for the...